Catalyst
Slingshot members are tracking this event:
Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 08, 2016
Occurred Source:
http://www.mrknewsroom.com/news/company-statements/merck-provides-update-filing-plans-omarigliptin-investigational-dpp-4-inhibi
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Dpp-4 Inhibitor, Omarigliptin, Type 2 Diabetes
